Stock MEGA-R MEGA LIFESCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mega Lifesciences Thailand S.E.

Equities

MEGA-R

TH4984010R19

End-of-day quote Thailand S.E.
Other stock markets
 18:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
38.25 THB +2.00% Intraday chart for Mega Lifesciences +4.79% -4.97%
05-13 Mega Lifesciences Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-23 Transcript : Mega Lifesciences Public Company Limited, 2023 Earnings Call, Feb 23, 2024

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MEGA LIFESCIENCES Stock Mega Lifesciences
-4.97% 908M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.36% 242B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.37% 224B
A+
NOVARTIS AG Stock Novartis AG
+13.03% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MEGA Stock
  4. MEGA-R Stock
  5. Ratings Mega Lifesciences